Namita Thapar’s Company Makes Semaglutide Injection More Affordable, Stock Surges 50% in a Year
Join Us
Follow Us
Emcure Pharmaceuticals cuts prices of its semaglutide injection Poviztra®, making weight management therapy more affordable in India, while the stock surges over 50 per cent in a year.
✨ AI Powered Summary
India is facing a growing public health challenge as obesity and weight-related health conditions continue to rise across the country.
Addressing this pressing concern, Emcure Pharmaceuticals Ltd has announced a significant price revision for its weight management drug Poviztra® (semaglutide injection) across India. Effective April 3, 2026, the reduced price will start at Rs. 3,999 per month for four weekly doses, making this clinically proven therapy more affordable to a wider patient base.
Poviztra® is a second brand of Novo Nordisk’s semaglutide injection, delivered in a convenient once-weekly pen device.
As the first Indian company to exclusively distribute and commercialise Poviztra®, Emcure aims to expand patient access to this effective therapy for obesity, backed by strong clinical and real-world evidence. The move comes at a time when affordable and accessible weight management solutions are urgently needed to combat the growing health risks associated with obesity.
All figures in Rs
| Dosage | Old Monthly Price (MRP incl. Taxes) | Revised Monthly Price (MRP incl. Taxes) |
| Poviztra® 0.25 mg | 8,790 | 3,999 |
| Poviztra® 0.5 mg | 11,200 | 4,999 |
| Poviztra® 1 mg | 11,200 | 5,999 |
| Poviztra® 1.7 mg | 13,000 | 7,999 |
| Poviztra® 2.4 mg | 15,000 | 8,999 |
About Emcure Pharmaceuticals Ltd
Emcure Pharmaceuticals Ltd (EPL), headquartered in Pune, is one of the leading Indian pharmaceutical companies established in 1981. The company is engaged in developing, manufacturing, and marketing a wide range of pharmaceutical products globally. Known for its focus on innovation, quality, and patient-centricity, Emcure is an R&D-driven organisation that offers differentiated therapies across several major therapeutic areas to improve patient health and well-being.
Emcure Pharmaceuticals Ltd Share Price Performance
On Thursday, Emcure Pharmaceuticals Ltd’s share price closed at RS 1,547.60, down Rs 42.50, or 2.67 per cent, from its previous close. During the trading session, the stock reached a high of Rs 1,585.50 and a low of Rs 1,457.00. Year-to-date, the stock has gained 10.72 per cent, while over the past year, it has risen by 50.22 per cent.
Disclaimer: The article is for informational purposes only and not investment advice.